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Abstract
Background An economic analysis from the perspective of
the UK National Health Service (NHS) evaluated the cost
effectiveness of lisdexamfetamine dimesylate (LDX)
compared with atomoxetine in children and adolescents
with attention-deficit/hyperactivity disorder who have had
an inadequate response to methylphenidate.
Methods A 1-year decision-analytic model was con-
structed, with the health outcomes ‘‘response’’, ‘‘nonre-
sponse’’, and ‘‘unable to tolerate’’. Clinical data were taken
from a head-to-head, randomized controlled trial in inad-
equate responders to methylphenidate. Response to treat-
ment was defined as a score of 1 (very much improved) or
2 (much improved) on the Clinical Global Impression–
Improvement subscale. Tolerability was assessed by dis-
continuation rates owing to adverse events. Utility weights
were identified via a systematic literature review. Health-
care resource use estimates were obtained via a survey of
clinicians. Daily drug costs were derived from British
National Formulary 2012 costs and mean doses reported in
the trial. One-way and probabilistic sensitivity analyses
(PSAs) were performed.
Results The comparison of LDX with atomoxetine resulted
in an estimate of an incremental cost-effectiveness ratio of
£1802 per quality-adjusted life-year (QALY). The result
was robust in a wide range of sensitivity analyses; results
were most sensitive to changes in drug costs and efficacy.
In the PSA, assuming a maximum willingness to pay of
£20,000 per QALY, LDX versus atomoxetine had an 86 %
probability of being cost effective. In 38 % of PSA runs,
LDX was more effective and less costly than atomoxetine.
Conclusions From the perspective of the UK NHS, LDX
provides a cost-effective treatment option for children
and adolescents who are inadequate responders to
methylphenidate.
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article (doi:10.1007/s40263-016-0354-3) contains supplementary
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Key Points
About one-third of patients have an inadequate
response to initial treatment with methylphenidate
and consequently might be considered for treatment
with atomoxetine or lisdexamfetamine dimesylate
(LDX).
In this patient population, LDX was associated with
a faster and more robust treatment response than
atomoxetine, as demonstrated in a 9-week, head-to-
head, randomized, double-blind, active-controlled
study.
An economic analysis, conducted using data from
the head-to-head trial, showed that LDX is a cost-
effective treatment option compared with
atomoxetine in children and adolescents who have
had an inadequate response to methylphenidate.
1 Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a
chronic neurobehavioral disorder that is estimated to affect
5.3 % of children worldwide, 5 % of European children,
and 6–6.5 % of children in North America [1, 2]. The core
symptoms of ADHD include inattention, impulsivity, and
hyperactivity [3]. It is associated with impairment that
affects not only the child but also parents and siblings,
causing disturbances to family and marital functioning, and
reduction in the overall quality of life [4, 5]. ADHD often
persists into adulthood, causing disruptions to both pro-
fessional and personal life [4] and imposes a considerable
cost on the healthcare system and society. In the USA, the
economic burden of ADHD in children and adolescents is
estimated to be between $US38 billion and $US72 billion
per year, of which healthcare cost estimates range between
$US21 billion and $US44 billion [6]. A review of Euro-
pean-based studies of ADHD-related costs estimated
annual average total costs to be between €9860 and
€14,483 per patient [7]. In Europe, the annual national
costs were estimated to be between €1041 and €1529
million [7], using the Netherlands as a reference country.
Management of ADHD usually includes psychotherapy
and behavioral therapy, parent training, medications, or a
combination of both psychotherapy and pharmacotherapy.
In the UK, the stimulant methylphenidate is a recom-
mended first-line treatment, with the nonstimulant ato-
moxetine considered for first-line treatment when tics,
Tourette’s syndrome, anxiety disorder, stimulant misuse, or
risk of stimulant diversion are present [8]. It has been
estimated that as many as 25–35 % of subjects in clinical
trials may have an inadequate response to initial stimulant
treatment [9]. In the UK, atomoxetine is the recommended
treatment option in patients who have had inadequate
response or are intolerant to methylphenidate [8, 10].
Atomoxetine was found to be a cost-effective option
compared with stimulant therapy (represented in the model
by methylphenidate and dexamphetamine) when evaluated
from the perspective of the National Health Service (NHS)
in the stimulant-exposed UK population [11].
Lisdexamfetamine dimesylate (LDX) is a pro-drug;
following absorption, LDX undergoes hydrolysis to dex-
amphetamine. LDX has been studied in several large,
phase III trials in children and adolescents and has been
shown to be effective in reducing the symptoms of ADHD.
Three trials in children and adolescents with ADHD were
placebo controlled [12–14], and one was a head-to-head
study versus atomoxetine in children and adolescents with
ADHD who have had an inadequate response to methyl-
phenidate (either immediate or extended release) [15]. In
the head-to-head study, the median time to first clinical
response, defined as a Clinical Global Impressions–Im-
provement (CGI-I) score of 1 (very much improved) or 2
(much improved), 95 % confidence interval (CI) was sig-
nificantly shorter for patients receiving LDX (12.0 days
[8.0–16.0]) than for those receiving atomoxetine
(21.0 days [15.0–23.0]) (p = 0.001) [15]. Moreover, at the
completion of the 9-week study period, a greater proportion
of patients achieved improved global functioning, as
measured by the CGI-I [16], designed to rate severity of
illness and improvement in symptom severity (103/126
patients [81.7 %] in the LDX group compared with 84/132
patients [63.6 %] in the atomoxetine group) [15]. Simi-
larly, a greater proportion of patients receiving LDX
experienced improvement in symptoms, as measured by
the ADHD Rating Scale-IV, designed to reflect current
symptomatology of ADHD based on Diagnostic and Sta-
tistical Manual of Mental Disorders, 4th edition, text
revision (DSM-IV-TR) criteria [17] (114/126 patients
[90.5 %] in the LDX group achieved response [defined as a
percentage reduction from baseline in the ADHD-RS-IV
total score of C25 %] compared with 102/133 patients
[76.7 %] in the atomoxetine group) [18]. Although esti-
mates of the time required for atomoxetine to reach its
maximum effect generally range from 4 to 6 weeks [8, 19],
one study suggests that it may take as long as 12 weeks
[20]. The objective of the present study is to estimate the
cost effectiveness of LDX compared with atomoxetine in
the treatment of children and adolescents with ADHD in
whom response to methylphenidate (either extended
release or immediate release) is considered clinically
inadequate. The results of the analysis are presented as the
total costs and total quality-adjusted life-years (QALYs)
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for each drug, as well as the incremental costs and QALYs
for LDX when compared with atomoxetine. The incre-
mental cost-effectiveness ratio (ICER) for LDX relative to
atomoxetine is also presented and evaluated against an
established cost-effectiveness threshold of £20,000 per
QALY [21].
2 Methods
A decision-tree model was developed in Microsoft Excel
(Microsoft Corp., Redmond, WA, USA) to evaluate the
cost effectiveness of LDX compared with atomoxetine
from the perspective of the UK NHS. The health outcomes
used in the model as the measures of benefit were ‘‘unable
to tolerate’’, ‘‘response’’, and ‘‘nonresponse’’ (Fig. 1). The
impact of using LDX as an alternative to atomoxetine in
terms of costs and outcomes was estimated in the model by
simulating the number of patients who achieved a response
to treatment and those who did not. Costs and utilities
corresponding to the patients’ health states were assigned
to each of these patients. The target population for the
analysis consisted of children and adolescents with ADHD
in whom response to methylphenidate was considered
clinically inadequate. An inadequate response to methyl-
phenidate, as defined in the LDX head-to-head study versus
atomoxetine [15] included, but was not limited to, one or
more of the following: the presence of some residual
ADHD symptoms; inadequate duration of action; variable
symptom control; as well as whether, in the opinion of the
investigator, the patient may benefit from an alternative to
methylphenidate [15]. The base-case analysis evaluated
direct medical costs and health-related quality of life
associated with 1 year of treatment, including the initial
28-day drug titration period. The time horizon of 1 year
was chosen to capture differences in the cost and benefits
for the time period of the clinical trial, given the lack of
long-term data comparing LDX and atomoxetine. The
dichotomous response modelling framework and key
assumptions, including the 1-year time horizon, were
adapted from the health technology assessment (HTA)
model used in an earlier assessment of ADHD drugs by the
UK National Institute for Health and Care Excellence
(NICE) [22].
2.1 Model Assumptions
Patients who inadequately responded to methylphenidate
entered the model when they initiated a course of treatment
with either LDX or atomoxetine.
Patients who experienced intolerable side effects dis-
continued treatment in the middle of the titration period,
i.e., after 14 days of treatment. The discontinuation of
patients’ utilities and costs during the titration period
(28 days) was represented by a 50/50 % mix of the
responder and nonresponder utility values and a 50/50 %
mix of the responder and nonresponder nondrug costs,
respectively.
Patients who discontinued treatment because of intoler-
able side effects did not initiate additional treatment because
they have failed both methylphenidate and a second-line
drug. Patients who discontinued because of intolerable side
effects had the same utilities and costs as nonresponders for
the remainder of the 1-year model time horizon.
Patients who responded to treatment at the end of the
titration period continued to receive treatment throughout
the model’s time horizon, maintaining their level of
response.
At the end of the titration period, nonresponding patients
discontinued all drug treatments and were assumed to stay
in the nonresponse health state for the remainder of the
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lack of response had immediate loss of treatment effect and
were assigned the associated costs and utilities throughout
the model’s time horizon.
The analysis compares LDX and atomoxetine adminis-
tered as directed in the head-to-head study [15]. We
assumed that patients who responded and tolerated treat-
ment were adherent and persistent with treatment over the
time horizon of the model, as was generally observed in the
head-to-head study. This assumption is consistent with that
made in the HTA model presented by King et al. [22].
Costs and benefits were not discounted, given the time
horizon of 1 year. The uncertainty in the ICER estimate
was explored by one-way and probabilistic sensitivity
analyses (PSAs).
Quality control of model programming and verification
of all input data with original sources was performed
according to a prespecified test plan by health economists
who were not involved in the model development.
2.2 Model Parameter Inputs
2.2.1 Efficacy and Safety
The base-case analysis used data generated from a head-to-
head clinical study that compared LDX versus atomox-
etine, the most commonly used second-line treatment in the
UK in patients with ADHD who were inadequate respon-
ders to previous methylphenidate therapy [15]. Head-to-
head randomized controlled trials are considered by NICE
to provide the most valid evidence of relative efficacy;
hence, this study was used in the economic analysis. That
study was a 9-week, head-to-head, randomized, double-
blind, active-controlled study (SPD489-317; ClinicalTri-
als.gov NCT01106430), with patients randomized 1:1 to an
optimized daily dose of LDX (30, 50, or 70 mg) or ato-
moxetine (patients\70 kg, 0.5–1.2 mg/kg with total daily
dose not exceeding 1.4 mg/kg; patients C70 kg, 40, 80, or
100 mg). Response to treatment, assumed in the model to
be measured at the end of the titration period, was defined
as a score of 1 (very much improved) or 2 (much
improved), based on the last observation carried forward
(LOCF) CGI-I score at week 9, which was the definition of
response used in the primary outcome. This definition was
also used in the trial to categorize patients into responders
and nonresponders, and this outcome was selected for use
in the economic analysis owing to its dichotomous nature.
Response rates applied in the base-case analysis are pre-
sented in Table 1.
Similar proportions of patients in the LDX and ato-
moxetine groups experienced treatment-emergent adverse
events: 92/128 (72 %) and 95/134 (71 %), respectively
[15]. Therefore, short-term drug-related adverse events
were not incorporated in the model. Patients’ drug
tolerability in the model was based on the rates of with-
drawal because of adverse events reported in the head-to-
head trial of LDX versus atomoxetine (6.3 and 7.5 %,
respectively) [15].
2.2.2 Health-State Utilities
A systematic review of the economic literature in ADHD
was conducted to identify utility values for inclusion in the
model (methods of this review are reported elsewhere
[31]). Utility estimates associated with response and non-
response from the study by Coghill et al. [24] were selected
as relevant for the economic analysis (Table 1). These
values were estimated using the EuroQol-5 Dimensions
instrument (EQ-5D), which is NICE’s preferred method for
obtaining utility values [21].
2.2.3 Resource Use and Costs
Healthcare resource utilization estimates associated with
response and nonresponse were obtained from a survey of
clinicians currently treating patients with ADHD in the UK
[27] (Table 2). The sample consisted of 21 specialists (18
from England, two from Scotland, and one from Wales); 13
of the specialists were psychiatrists, the remaining eight
were pediatricians. Unit costs from 2011–2012 UK
national sources were applied to the resource utilization
estimates to calculate the costs associated with nondrug
healthcare resources used by responders and nonrespon-
ders. In the survey, items of healthcare resource were based
on those reported by King et al. [22].
Drug unit costs were obtained from the British
National Formulary 2012 [29]. Drug doses used were the
mean doses for the titration and maintenance periods as
reported in the head-to-head trial. Drug costs were cal-
culated using the head-to-head trial mean doses and per-
milligram drug costs. Each per-milligram cost was based
on the cost of a pack with the tablet size closest to the
given mean dose.
2.3 Sensitivity Analyses
2.3.1 One-Way Sensitivity Analysis
The following summarizes the variables considered in the
one-way sensitivity analysis (Table 1).
Response rates The base-case analysis used a definition
of treatment response based on the LOCF CGI-I measure at
week 9. A sensitivity analysis applied response rates based
on the ADHD Rating Scale-IV measure, using a reduction
of 25 % or greater in ADHD Rating Scale-IV score (the
most commonly used threshold in ADHD trials [23]),
assessed using the result at week 9 or a non-response for
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Table 1 Summary of model input parameters
Description Analysisa Value Range Distribution Source
Treatment-specific response rates
Response defined as the proportion of patients with a CGI-I value of 1 (very much improved) or 2 (much improved) out of all patients includedb
LDX Base 81.7 % 75.0–88.5 % Beta [15]
ATX Base 63.6 % 55.4–71.8 % Beta [15]
LDX SA 70.3 %
RR = 3.218
2.683–3.860 Log-normalc MTC [23]
ATX SA 45.4 %
RR = 2.077
1.782–2.419 Log-normalc MTC [23]
Response defined as the proportion of patients with a percentage reduction from baseline in ADHD-RS-IV total score of C25 %d
LDX SA 72.4 % 64.7–80.2 % Beta Head-to-head trial data [18]
ATX SA 63.7 % 55.6–71.8 % Beta Head-to-head trial data [18]
Treatment-specific withdrawal owing to AE rates
LDX Base 6.25 % NR Beta [15]
ATX Base 7.5 % NR Beta [15]
LDX SA 3 %
RR = 2.871
0.942–8.755 Log-normalc MTC [23]
ATX SA 1.7 %
RR = 1.669
0.836–3.331 Log-normalc MTC [23]
Health-state utilities
Responder Base 0.837 NR Beta EQ-5D [24]
Nonresponder Base 0.773 NR Beta EQ-5D [24]
Responder SA 0.820 SE = 0.19 Beta HUI2 [25]
Nonresponder SA 0.700 SE = 0.20 Beta HUI2 [25]
Responder SA 0.926 0.915–0.938 Beta Head-to-head trial data analysis [26]
Nonresponder SA 0.905 0.886–0.924 Beta Head-to-head trial data analysis [26]
Health-state costs (each 28 days)
Responder Base £99.78 £78.82–119.74 Uniform
(±20 %)
Resource use estimates [27]
Unit costs [28]
Nonresponder Base £190.25 NA Uniform
(±20 %)
Resource use estimates [27]
Unit costs [28]








Responder SA £93.38, £80.57,
£67.76
Not included Not included -10 %,-30 %, -50 % specialist visit vs. junior doctor
assumptione
Nonresponder SA £177.59, £152.26,
£126.94
Not included Not included -10 %,-30 %, -50 % specialist visit vs. junior doctor
assumptione
Drug costs (per 28 days)
LDX Base £83.02 (titration)
£72.28 (post
titration)f
Not included Not included Usage [18]
Unit costs [29]
ATX Base £82.43 (titration)
£63.03 (post
titration)f
Not included Not included Usage [18]
Unit costs [29]
CUA of Lisdexamfetamine in Children and Adolescents with ADHD 989
those not assessed at week 9 (non-responder imputation
[NRI] approach). The NRI-based value for ADHD-RS
score rather than the LOCF-based value was chosen to
explore how the cost-effectiveness results would change
when the LDX response rate decreased while the ato-
moxetine rate remained roughly the same. A further sen-
sitivity analysis used response rates from a mixed-
treatment comparison (MTC) analysis conducted using
ADHD clinical trials in a broad ADHD population (rather
than in patients with inadequate response to methylpheni-
date who represented the model target population)
(Table 1). Despite this difference in the populations, the
MTC results were used in the sensitivity analysis to explore
the impact of utilizing all published clinical evidence in the
model. Systematic literature review and MTC methods
used are presented in the Electronic Supplementary Mate-
rial (ESM) Resource 1 and 2, with further details reported
elsewhere [23]; the search strategy is presented in ESM
Resource 3.
Utility values In the base-case analysis, the model
applied health-state utility estimates reported by Coghill
et al. [24], who used the EQ-5D instrument to obtain
utility values. The sensitivity analysis applied alternative
utility values reported by Lloyd et al. [25], who used
statistical mapping to derive utilities for responder and
nonresponder health states defined using the CGI-I
measure. A further sensitivity analysis applied utility
data from the LDX versus atomoxetine head-to-head
trial in patients who had an inadequate response to
methylphenidate (Table 1) [26]. These utility values
were considered particularly valuable as they were
derived from the population studied in the head-to-head
trial. Patients in that study were evaluated using the
Health Utilities Index Mark 2 (HUI2) [33]. The self-
administered, proxy-assessed version of the HUI2 con-
sists of 15 questions used to classify a patient’s health
status. In the trial, the proxy was the patient’s parent or
legally authorized representative.
Resource use estimates The base-case analysis used the
healthcare resource use estimates obtained from a survey of
UK specialists. In the sensitivity analysis, these resource
use estimates were replaced by the values reported in the
HTA model [22]. To calculate the costs, the 2011–2012
UK resource unit costs were applied to these alternative
values. In additional sensitivity analyses, a percentage of
the visits to specialists were assumed to be consultations
Table 1 continued
Description Analysisa Value Range Distribution Source
LDX SA £83.02 (titration)
£66.56 (post
titration)g
Not included Not included Usage [30]
Unit costs [29]
ATX SA £82.43 (titration)
£107.77 (post
titration)g
Not included Not included Usage [30]
Unit costs [29]
ADHD-RS-IV Attention-Deficit/Hyperactivity Disorder Rating Scale-IV, AE adverse event, ATX atomoxetine, CGI-I Clinical Global Impression–
Improvement subscale, EQ-5D EuroQol 5-Dimensions instrument, HUI2 Health Utilities Index Mark 2, LDX lisdexamfetamine dimesylate,MTC
mixed-treatment comparison, NA not applicable, NR not reported, PSA probabilistic sensitivity analysis, RR relative risk, SA sensitivity analysis,
SE standard error
a Base-case analysis or sensitivity analysis
b Assessed as the last observation carried forward at week 9
c The MTC outputs for response and discontinuation because of AEs were provided as RRs versus placebo. These RRs were converted in the
economic model to rates using the MTC pooled placebo rates (0.218 for response and 0.010 for withdrawals). To generate PSA values, sampling
was performed on RRs using log-normal distributions
d Assessed using the result at week 9 or a non-response for those not assessed at week 9 (a non-response imputation approach to dealing with
missing data)
e This proportion of visits to a specialist (psychiatrist or pediatrician) was costed using the unit cost for a visit to a junior doctor (foundation
house officer 1 at £43 per h) rather than as a visit to a consultant
f This method of drug costing uses the mean doses from the head-to-head trial. In calculating the daily drug costs applied in the model, the mean
daily doses for titration and post-titration periods were multiplied by the per-milligram costs. Each per-milligram cost was based on the cost of a
package with a tablet size closest to the given mean daily dose. Per-cycle cost was based on a daily cost multiplied by 28 days
g This method of drug costing was derived from the average daily number of tablets consumed, as reported in the IMS database [30]. To
calculate daily drug costs, the daily number of tablets consumed, split by tablet strength, was multiplied by the corresponding tablets’ unit costs
and then weighted by the corresponding prescription volumes. The estimates of daily consumption and the prescription shares for LDX’s
different tablet strengths were based on the IMS data collected in Brazil and Canada (where LDX has been used in clinical practice)
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with junior doctors and were costed accordingly. Three
analyses were performed by replacing 10, 30, and 50 % of
specialist visits to pediatricians or psychiatrists with visits
to junior doctors.
Drug-costing method The base-case analysis used a
method of drug costing whereby the mean daily doses
from the trial were used to calculate the daily drug costs.
The sensitivity analysis explored the effect of applying
the drug costs calculated from real-world drug utilization,
rather than from drug usage reported in the trial. The real-
world usage data were obtained from Canada and Brazil,
where LDX has been used in clinical practice. These data
were reported as the daily average consumption, pre-
sented by the numbers of tablets [30]. To calculate the
corresponding costs, the tablet numbers were multiplied
by tablet unit costs.
2.3.2 Probabilistic Sensitivity Analysis
Uncertainty in model input parameters was examined in
PSAs, wherein all input parameters, apart from drug costs,
which were known with certainty, were simultaneously
varied using prespecified distributions reflecting the
uncertainty about their true values. The prespecified dis-
tributions for each parameter included in the PSA are
presented in Table 1; 1000 repeated model simulations
were performed. The PSA was performed using the base-
case input parameter values and using two alternative
scenarios: one using efficacy distributions estimated from
the MTC, and one using utility weight distributions cal-
culated from the head-to-head trial data. PSA results for the
base-case analysis were presented graphically in the form
of a cost-effectiveness acceptability curve.
3 Results
3.1 Base-Case Analysis
The base-case analysis results are presented in Table 3.
Over a time horizon of 1 year, a patient receiving LDX
benefitted from 0.011 additional QALYs compared with a
patient receiving atomoxetine. The estimated mean per-
patient drug cost was £745 in the LDX arm and £525 in the
atomoxetine arm; a difference of £220 between arms. The
per-patient nondrug cost was £1607 and £1807 for patients
receiving LDX and atomoxetine, respectively; thus, total
costs were £2352 for LDX and £2332 for atomoxetine. The
ICER of using LDX versus atomoxetine was estimated as
(£2352–2332)/0.011 = £1802 per QALY (note: calcula-
tions used unrounded values).
3.2 One-Way Sensitivity Analysis
The results of the one-way sensitivity analyses are sum-
marized in Fig. 2 and Table 4. The results of the model
were found to be robust to changes in the majority of the
model input parameter values. The model was most sen-
sitive to changes in assumptions about drug costs and to the
use of MTC-generated response rates, with the direction of
results changing from LDX being cost effective in the base
case to LDX being dominant—that is, LDX was more
effective and less costly.
3.3 Probabilistic Sensitivity Analysis
The mean probabilistic ICER for the base-case analysis
was estimated to be £1586 per QALY. When assuming an
acceptable willingness to pay of £20,000 per QALY [21],
LDX had an 86 % probability of being cost effective when
Table 2 Resource use and costs applied in the base-case analysis
Resource item Unit cost Units per year Average cost per year
Responders
Psychiatrista £261.87 2.48 £649.44
Pediatricianb £167.41 2.33 £390.07
GPc £43.00 2.62 £112.66
Nursed £49.00 2.71 £132.79
Blood teste £3.09 0.42 £1.30
ECGf £60.73 0.18 £10.93
Total – – £1297
Nonresponders
Psychiatrista £261.87 5.19 £1359.11
Pediatricianb £167.41 4.1 £686.38
GPc £43.00 4.24 £182.32
Nursed £49.00 4.48 £219.52
Blood teste £3.09 0.72 £2.22
ECGf £60.73 0.39 £23.68
Total – – £2473
ECG electrocardiogram, GP general practitioner, NHS National
Health Service
a Source: NHS Trusts and NHS Foundation Trusts: Mental Health—
Outpatient Attendances. MHOP05—Children and Adolescent Other
Services [28]
b Source: NHS Trusts and NHS Foundation Trusts: Consultant Led—
Follow up Attendance Non-Admitted Face to Face. 420—Paediatrics
[28]
c Source: 10.8b General practitioner—unit costs. Per surgery con-
sultation lasting 11.7 min [32]
d Source: 10.4 Nurse specialist [community]—unit costs. Per h [32]
e Source: NHS Trusts and NHS Foundation Trusts: Direct Access—
Pathology Services. DAP823—Haematology [Excluding Anti-Coag-
ulant Services] [28]
f Source: NHS Trusts and NHS Foundation Trusts: Direct Access—
Diagnostic Services. EA47Z—Electrocardiogram Monitoring and
Stress Testing [28]
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compared with atomoxetine (Fig. 3). The PSA was also
performed for the additional two scenario analyses. For the
analysis using alternative efficacy estimates from the MTC,
the mean probabilistic ICER showed that LDX was a
dominant strategy compared with atomoxetine. For the
analysis using utility weight distributions from the head-to-
head trial, the mean probabilistic ICER was estimated at
£4968 per QALY, with a 62 % probability that the ICER
fell below a threshold value of £20,000 per QALY.
4 Discussion
ADHD in children and adolescents can be successfully
treated pharmacologically, and stimulants are the first-line
treatment option. However, about one-third of patients
have an inadequate response to initial treatment with
methylphenidate, and atomoxetine is typically used in this
patient population. In a head-to-head, randomized con-
trolled trial, LDX was shown to provide more rapid and
superior symptom control than atomoxetine in children and
adolescents with an inadequate response to methylpheni-
date. Our economic analysis used the results of the head-to-
head trial to assess the cost effectiveness of LDX when
compared with atomoxetine. The base-case results showed
that LDX was a cost-effective option when compared with
atomoxetine, with an ICER of £1802 per QALY gained.
Moreover, when we used the results of the MTC as clinical
inputs, therefore accounting for all available published
evidence in this ADHD population, the model results
showed that LDX was a dominant strategy. Sensitivity
analyses confirmed the robustness of the results, showing a
high likelihood of LDX being cost effective relative to
atomoxetine when applying probabilistic methods.
Our model has underlying assumptions similar to those
of other models used to assess the cost effectiveness of
drug therapies for ADHD. The cost effectiveness of ato-
moxetine in stimulant-exposed UK populations was pre-
viously assessed from the NHS perspective by Cottrell
et al. [11]. That study showed that inclusion of atomoxetine
in the treatment algorithm was cost effective under the
established threshold of £20,000 per QALY in stimulant-
Basecase
(£1,802 per QALY)
Incremental cost effectiveness ratio (£/QALY) 
Model input parameter
-£35000 -£30000 -£25000 -£20000 -£15000 -£10000 -£5000 £0 £5000 £10000
Resource use (assuming 10% of specialist 
visits with a junior doctor) £3,072
Health-state utility (using utilities from head-to-
head trial) [26] £5,490
Health-state utility (using alternative 
estimates from published literature) [24] £961
Resource use (using alternative 
estimates from published literature) [21] £9,338
Resource use (assuming 30% of 
specialist visits with a junior doctor) £5,614
Resource use (assuming 50% of 
specialist visits with a junior doctor) £8,156
Treatment efficacy (using MTC-generated 
CGI-I-based response rates) [22] -£2,668
Treatment efficacy (using ADHD-RS-IV definition 
from head-to-head trial) [18]
 
£7,776
Drug-costing method (using real-world drug utilization) 
[30] -£31,959
Fig. 2 Summary of sensitivity analysis results. ADHD-RS-IV Attention-Deficit/Hyperactivity Disorder Rating Scale-IV, CGI-I Clinical Global
Impression–Improvement subscale, MTC mixed-treatment comparison, QALY quality-adjusted life-year
Table 3 Base-case analysis results (per patient)
Strategies Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£/QALY)
ATX 2332 0.8092 – – –
LDX 2352 0.8202 19.68 0.011 1802
ATX atomoxetine, ICER incremental cost-effectiveness ratio, LDX lisdexamfetamine dimesylate, QALY quality-adjusted life-year
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failed or stimulant-contraindicated populations. NICE’s
current clinical recommendations for the management of
ADHD in children and adolescents are based on a cost-
effectiveness analysis assessing methylphenidate, atomox-
etine, and dexamphetamine [22]. The optimal treatment
strategy identified by that analysis suggested that methyl-
phenidate should be used in first line, dexamphetamine in
second line, with atomoxetine in third line. It also con-
cluded that, for patients contraindicated to stimulants,
atomoxetine is preferred to no treatment.
Our model found that LDX is highly cost effective rel-
ative to atomoxetine, providing better efficacy at a small
increased cost. Thus, LDX would provide a good additional
second-line stimulant option. The option of using LDX
may be particularly valuable for patients for whom ato-
moxetine is contraindicated or for those patients who prefer
a stimulant with an adverse-event profile that is similar to
that of other established stimulants. Thus, the inclusion of a
new cost-effective option in the armamentarium of ADHD
treatments could allow for patients’ individual needs and
preferences to be taken into consideration. Having multiple
stimulant and nonstimulant treatment options available is
likely to contribute to a reduction in the overall burden of
ADHD.
The previous HTA economic evaluation [22] acknowl-
edged the lack of clinical evidence to fully assess differ-
ences between various ADHD treatments. In contrast, our
economic analysis used evidence generated by a random-
ized, head-to-head controlled trial that is considered to be
at the top of the hierarchy of evidence [21, 34], although
we acknowledge that certain elements of the study design
(the 9-week duration and once-daily dosing regimen) may
not have elicited the maximum potential treatment benefit











































Base case 19.68 0.011 1802
Treatment efficacy (using ADHD-RS-IV definition from head-to-head trial) [18] 42.89 0.006 7776
Treatment efficacy (using MTC-generated CGI-I-based response rates) [23] -38.79 0.015 Dominant: -2668
Health-state utility (using alternative estimates from published literature) [25] 19.68 0.021 961
Health-state utility (using utilities from head-to-head trial) [26] 19.68 0.004 5490
Resource use (using estimates reported in King et al. [22]) 102.00 0.011 9338
10 % of specialist visits with a junior doctor 33.56 0.011 3072
30 % of specialist visits with a junior doctor 61.32 0.011 5614
50 % of specialist visits with a junior doctor 89.08 0.011 8156
Drug-costing method [30] -349.08 0.011 Dominant: -31,959
ADHD-RS-IV Attention-Deficit/Hyperactivity Disorder Rating Scale-IV, CGI-I Clinical Global Impression–Improvement subscale, ICER
incremental cost-effectiveness ratio, MTC mixed-treatment comparison, QALY quality-adjusted life-year
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sensitivity analysis using the results of an MTC where all
clinical trials of atomoxetine were included, including
those with different durations and dosing patterns. The
results using the outputs of the MTC were more favorable
for LDX than those using the results of the clinical trial.
Another strength of our analysis is that our model used a
model structure and timeframe of 1 year. This timeframe is
consistent with that used in other UK-based models
[11, 22, 35] and requires minimal extrapolation of the
short-term data from the head-to-head trial, thus recog-
nizing the lack of the long-term data that would be nec-
essary to adequately inform a longer-term model.
Our study has a number of limitations that need to be
considered, particularly when assessing its generalizability.
However, to avoid speculation, the effects of these limita-
tions on the model outcomes are not fully explored, given
that relevant data are not available to enable these alternative
analyses. First, the study was conducted from the UK NHS
perspective and did not include the broader societal per-
spective, which is an important cost driver in the overall cost
burden of ADHD. Taking into account costs associated with
the societal perspective would likely result in a lower ICER
for LDX. Second, the clinical data used in the analysis were
derived from a single clinical trial set mainly outside of the
UK. However, the European Medicines Agency considered
these clinical data to be applicable to all European Union
countries. Third, although this trial’s strength was in its
head-to-head randomized, double-blind, parallel-group,
dose-optimized design, the 9-week duration might not have
elicited the maximum potential treatment benefit of ato-
moxetine as it has been suggested that 12 weeks is needed
for atomoxetine to reach maximum response [20]. Fourth,
despite evidence to suggest that LDX provides better
adherence and persistence than atomoxetine [36, 37], the
model did not consider real-life medication adherence
because of the lack of data on the relationship between
adherence to therapy and symptom reduction. Fifth, because
of a lack of data, the study did not consider any treatment for
nonresponders and assumed these patients discontinued
drug therapy. Sixth, the utility data for intolerable side
effects were not based on disutility data of individual side
effects leading to discontinuation, but estimated in the
model as a 50/50 % mix of the responder and nonresponder
utility values. In real-world clinical practice, such patients
may receive off-label medications (such as bupropion,
clonidine, modafinil, and imipramine) or combination
treatments [8]. Seventh, cost effectiveness of any treatment
can change over time as clinical practice and medication
pricing evolves. Finally, the comparisons that could be
performed in this economic analysis were restricted to ato-
moxetine only because of a lack of data on other possible
comparators, such as dexamphetamine.
5 Conclusions
The findings from this study support the use of LDX in
the UK as a more cost-effective treatment option than
atomoxetine in the treatment of children and adolescents
who have experienced unsatisfactory improvements on
methylphenidate.
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